Radioligand
Therapy (RLT) Market: Introduction
·
Radioligand therapy (RLT) is a targeted therapeutics
option for a cancer treatment. Radiopharmaceutical is infused or injected into
a peripheral vein. Ligands are labelled with radioactive isotopes, mostly
beta-emitters, such as lutetium-177. High rate of long-lasting tumor remission
and stabilization can be achieved using radioligand therapy (RLT).
·
Radioligand
therapy (RLT) is a systemic therapy which is used in metastasized disease
treatment. In radioligand therapies, radiopharmaceuticals bind to a tumor
target.
·
NET radioligand therapy is also known as peptide-receptor
radionuclide therapy (PRRT). NET peptides targeting the somatostatin-receptor
(SSTR) are used for treatment of neuroendocrine tumors.
·
For prostate cancer treatment, radioligand specifically
binds prostate-specific membrane antigen (PSMA). Prostate-specific membrane
antigens (PSMA) are overexpressed in prostate cancer.
Request
a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74355
Key Drivers
of Global Radioligand Therapy (RLT) Market
·
The global radioligand therapy market is likely to be
driven by increase in footprint of pharmaceutical manufacturers in potential
markets in Asia Pacific, Latin America, and Middle East & Africa
·
Research & development of radioligand therapy
candidate to treat a broad range of cancer types is expected to propel the
global radioligand therapy treatment market during the forecast period.
Endocyte's Lu-PSMA-617 is a radioligand therapy candidate which is currently
under phase III clinical trial for treatment of prostate cancer.
Request for Analysis of COVID19 Impact on Radioligand
Therapy (RLT) Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74355
·
Increase in prevalence of cancer across the globe is
expected to fuel the market growth during the forecast period. According to the
American Cancer Society, in 2019, around 174,650 new cases for prostate cancer
were diagnosed in the U.S.
·
Strategic acquisition by leading players operating in
radioligand therapy is helping manufacturers in expanding cancer product
pipeline. Thus, approval and commercialization of pipeline products in the near
future is expected to propel the market during the forecast period.
·
In October 2018, Novartis underwent purchase agreement
with Endocyte to purchase Endocyte's Lu-PSMA-617 clinical product
Request
For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=74355
North
America to Hold Major Share of Global Radioligand Therapy (RLT) Market
·
North America is projected to lead the market during the
forecast period. North America is the leading market for radioligand therapy
(RLT) driven by high rate of adoption of radioligand therapy products after FDA
approval. According to Novartis, Lutathera has been prescribed to over 1,100
patients in the U.S.
·
Increase in awareness about the radioligand therapy and
rise in patient base suffering from cancer in the U.S. are expected to drive
the market in the region. Manufacturers are focused to enter into partnership
with laboratories for research & development of radioligand therapy
candidate which is anticipated to propel the market in the U.S.
Pre-Book Radioligand Therapy (RLT) Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=74355<ype=S
·
Governments in Europe have favorable reimbursement
policies. Furthermore, increase in research laboratories, rise in prevalence of
cancer, and increase in funding provided by governments are anticipated to
propel the market in the region during the forecast period.
More Trending Reports by Transparency Market Research:
https://www.prnewswire.com/news-releases/technological-advancements-and-innovations-to-fuel-growth-of-soft-tissue-repair-market-from-2018-to-2026-tmr-301168624.html
https://www.prnewswire.com/news-releases/global-oral-contraceptive-pills-market-projected-to-expand-at-6-cagr-rising-number-of-unplanned-pregnancies-drives-market-demand-tmr-301171827.html
About Us
Transparency Market Research (TMR) is a market
intelligence company, providing global business information reports and
services. Our exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers. TMR’s
experienced team of analysts, researchers, and consultants use proprietary
data sources and various tools and techniques to gather and analyze
information. Our business offerings represent the latest and the most reliable
information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different
sector - such as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These reports
provide in-depth analysis and deep segmentation to possible micro levels. With
wider scope and stratified research methodology, TMR’s syndicated reports
thrive to provide clients to serve their overall research requirement.
Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
